Core Viewpoint - Weigao Blood Purification plans to acquire 100% equity of Weigao Puri Pharmaceutical Packaging for an assessed value of 8.511 billion yuan, marking a significant asset restructuring and expanding its business into pharmaceutical packaging [2] Group 1: Acquisition Details - The acquisition will be fully paid through the issuance of shares, with Weigao Co. and its concerted parties increasing their stake in Weigao Blood Purification to 84.36%, maintaining absolute control [2] - Weigao Puri, established in 2018, specializes in pre-filled drug delivery systems and automatic safety drug delivery systems, aiming to provide comprehensive drug delivery solutions for global biopharmaceutical companies [2] Group 2: Financial Performance - As of June 30, 2025, Weigao Puri reported total assets of 3.425 billion yuan, total liabilities of 730 million yuan, and equity of 2.695 billion yuan, with a revenue of 939 million yuan and a net profit of 327 million yuan in the first half of 2025, indicating strong profitability [2] Group 3: Market Position - Weigao Puri has broken the overseas technology monopoly and holds a leading position in the domestic pre-filled product market, with over 50% market share from 2022 to 2024, ranking first domestically and among the top five internationally [3] Group 4: Strategic Rationale - The acquisition aims to diversify business operations and achieve technological synergy, allowing Weigao Blood Purification to leverage Weigao Puri's expertise in pharmaceutical packaging to expand its product line and reduce risks associated with a single business area [4] - The growing biopharmaceutical industry in China, projected to reach 534.8 billion yuan in 2024 and 1.13 trillion yuan by 2032, presents significant opportunities for both pharmaceutical packaging and upstream biopharmaceutical materials [4]

Core Viewpoint - Weigao Blood Purification plans to acquire 100% equity of Weigao Purui Pharmaceutical Packaging for an assessed value of 8.511 billion yuan, marking a significant asset restructuring and expanding its business into pharmaceutical packaging [1] Company Summary - Weigao Purui, established in 2018, specializes in pre-filled drug delivery systems and automatic safety drug delivery systems, providing comprehensive drug delivery solutions for global biopharmaceutical companies [1] - As of June 30, 2025, Weigao Purui reported total assets of 3.425 billion yuan, total liabilities of 730 million yuan, and owner’s equity of 2.695 billion yuan, with a revenue of 939 million yuan and a net profit of 327 million yuan for the first half of 2025, indicating strong profitability [1] Market Position - Weigao Purui has broken the overseas technology monopoly and holds a leading position in the domestic pre-filled product market, with a market share exceeding 50% from 2022 to 2024, ranking first domestically and among the top five internationally [2] Strategic Rationale - The acquisition aims to diversify Weigao Blood Purification's business and enhance technological synergy, allowing it to expand from blood purification products to the pharmaceutical packaging sector, thereby reducing risks associated with a single business area [3] - Weigao Purui's established biopharmaceutical customer resources will provide Weigao Blood Purification with ready sales channels for its biopharmaceutical filter business, facilitating mutual empowerment in technology and market access [3] Industry Context - The acquisition aligns with the rapid growth of the domestic biopharmaceutical industry, with the market expected to reach 534.8 billion yuan in 2024 and grow to 1.13 trillion yuan by 2032, driving demand for pharmaceutical packaging and upstream biopharmaceutical consumables [3] - The acceleration of the domestic supply chain for biopharmaceuticals, supported by policies and market demand, presents development opportunities for local companies with technological advantages [3]